Tepotinib Pregnancy and Breastfeeding Warnings
Tepotinib is also known as: Tepmetko
Tepotinib Pregnancy Warnings
Animal studies have revealed evidence of malformations at doses lower than human exposures. There are no controlled data in human pregnancy.
US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D and X are being phased out.
This drug should be used during pregnancy only when clearly necessary.
US FDA pregnancy category: Not Assigned
Risk Summary: Based on animal studies and its mechanism of action, this drug can cause fetal harm.
Comments:
-Advise pregnant women of the potential risk to a fetus.
-Verify the pregnancy status of females of reproductive potential prior to treatment initiation.
-Advise females of reproductive potential or males with female partners of reproductive potential to use effective contraception during treatment and for one week after the last dose.
Tepotinib Breastfeeding Warnings
Breastfeeding should be avoided.
Excreted into human milk: Data not available
Excreted into animal milk: Data not available
Comments:
-Advise women not to breastfeed during treatment and for one week following the last dose.
-There are no data regarding the secretion of this drug or its metabolites in human milk or its effects in the nursing infant or milk production.
References for pregnancy information
- "Product Information. Tepmetko (tepotinib)." EMD Serono Inc, Rockland, MA.
References for breastfeeding information
- "Product Information. Tepmetko (tepotinib)." EMD Serono Inc, Rockland, MA.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.